{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:56Z","timestamp":1787009456312,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extramammary Paget\u2019s disease (EMPD) is a rare cancer without standard therapy. We evaluated the safety and efficacy of a combination of the humanized monoclonal antiprogrammed death-1 (PD-1) antibody, carelizumab, with rivoceranib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients with advanced EMPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, single-arm, phase II trial included 12 patients with EMPD. The primary endpoint is the objective response rate (ORR), defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. It is hypothesized that the ORR will be less than 10% if the treatment is ineffective and will reach 35% if effective. Secondary endpoints include progression-free survival (PFS) and safety assessments. Eligible patients are aged \u226518 years, with histologically confirmed advanced EMPD. Treatment consists of carelizumab (200\u00a0mg intravenously every 3 weeks) and rivoceranib (250\u00a0mg orally once daily), with dose adjustments permitted based on toxicity profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between June 2024 and February 2025, 12 patients were enrolled. One patient withdrew from the trial because of nontreatment-related accidents, and a total of 11 patients completed at least 1 cycle of treatment. The median PFS is 2.4 months (95% CI, 2.1-4.4 months). Among these 11 patients, no patients achieved CR or PR. Six patients (50%) experienced grade 3 adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first trial evaluating the combination of a PD-1 inhibitor and a VEGFR inhibitor in advanced EMPD. This combination therapy is well tolerated but does not appear to have clinically meaningful activity in advanced EMPD. This trial was registered at the Chinese Clinical Trial number registration: 2400086153.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf202","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:44:27Z","timestamp":1751355867000},"source":"Crossref","is-referenced-by-count":4,"title":["Carelizumab and rivoceranib for advanced extramammary Paget\u2019s disease: an investigator-initiated multicenter, single-arm, phase II trial"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-6951","authenticated-orcid":false,"given":"Sheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Medical Oncology, Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Ju","sequence":"additional","affiliation":[{"name":"Medical Oncology, Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai University of Engineering Science , Shanghai 201620 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences , Jinan 250117 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences , Jinan 250117 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjun","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2025073107404468400_CIT0001","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary Paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025073107404468400_CIT0002","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fonc.2018.00038","article-title":"Metastatic extramammary Paget\u2019s disease: pathogenesis and novel therapeutic approach","volume":"8","author":"Fukuda","year":"2018","journal-title":"Front Oncol."},{"key":"2025073107404468400_CIT0003","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaad.2024.05.025","article-title":"Epidemiology of extramammary Paget\u2019s disease among Asian-American subgroups: a surveillance, epidemiology, and end results (SEER) program-based analysis","volume":"91","author":"Joshi","year":"2024","journal-title":"J Am Acad Dermatol."},{"key":"2025073107404468400_CIT0004","doi-asserted-by":"publisher","first-page":"e15030","DOI":"10.1111\/exd.15030","article-title":"Recent treatment and prognosis in 643 patients with extramammary Paget\u2019s disease","volume":"33","author":"Hatta","year":"2024","journal-title":"Exp Dermatol."},{"key":"2025073107404468400_CIT0005","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol."},{"key":"2025073107404468400_CIT0006","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000514345","article-title":"Treatment of metastatic extramammary paget disease with combination ipilimumab and nivolumab: a case report","volume":"14","author":"Guercio","year":"2021","journal-title":"Case Rep Oncol."},{"key":"2025073107404468400_CIT0007","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/1346-8138.17500","article-title":"Extramammary Paget\u2019s disease treated with of anti-programmed cell death protein 1 therapy after docetaxel therapy failure","volume":"52","author":"Narasaki","year":"2025","journal-title":"J Dermatol."},{"key":"2025073107404468400_CIT0008","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.ejcskn.2023.100002","article-title":"Molecular profiling of anal Paget\u2019s disease and underlying anal adenocarcinoma highlights their common origin","volume":"1","author":"Bellahsen-Harrar","year":"2023","journal-title":"EJC Skin Cancer"},{"key":"2025073107404468400_CIT0009","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy","volume":"16","author":"Niu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025073107404468400_CIT0010","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet."},{"key":"2025073107404468400_CIT0011","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"key":"2025073107404468400_CIT0012","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol."},{"key":"2025073107404468400_CIT0013","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/DAD.0000000000001622","article-title":"PD-L1 expression in extramammary Paget disease: a case series","volume":"43","author":"Fowler","year":"2021","journal-title":"Am J Dermatopathol."},{"key":"2025073107404468400_CIT0014","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/ijd.IJD_341_18","article-title":"Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary Paget\u2019s disease","volume":"66","author":"Goto","year":"2021","journal-title":"Indian J Dermatol."},{"key":"2025073107404468400_CIT0015","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/jdv.16145","article-title":"The Warburg effect and tumour immune microenvironment in extramammary Paget\u2019s disease: overexpression of lactate dehydrogenase A correlates with immune resistance","volume":"34","author":"Urata","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf202\/63900186\/oyaf202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf202\/63900186\/oyaf202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T11:40:48Z","timestamp":1753962048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf202\/8219902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf202","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf202"}}